Confidence Region Approach for Assessing Bioequivalence and Biosimilarity Accounting for Heterogeneity of Variability
For approval of generic drugs, the FDA requires that evidence of bioequivalence in average bioequivalence in terms of drug absorption be provided through the conduct of a bioequivalence study. A test product is said to be average bioequivalent to a reference (innovative) product if the 90% confidenc...
Saved in:
Main Authors: | Jianghao Li, Shein-Chung Chow |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Probability and Statistics |
Online Access: | http://dx.doi.org/10.1155/2015/298647 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain
by: Alexis Oliva, et al.
Published: (2024-11-01) -
Comparison of Innovative and Conventional Methods in Biosimilar Bridging Studies with Multiple References
by: Pong A, et al.
Published: (2024-12-01) -
Comparative study on the bioavailability and bioequivalence of rifapentine capsules in humans
by: Ying Qi, et al.
Published: (2025-01-01) -
Ustekinumab Biosimilars
by: Elena Carmona-Rocha, et al.
Published: (2024-11-01) -
Bioequivalence study of fluticasone propionate nebuliser suspensions in healthy Chinese subjects
by: Feng Cheng, et al.
Published: (2025-01-01)